3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Kidney Neoplasms
5
von Hippel-Lindau Disease
4
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Temozolomide
3
sargramostim
2
montanide ISA 51
2
lutetium Lu 177 dotatate
2
incomplete Freund's adjuvant
2
Sunitinib
2
Octreotide
2
Everolimus
2
Colony-Stimulating Factors
2
Capecitabine
2
sapanisertib
1
lanreotide
1
fludarabine phosphate
1
cabozantinib
1
belzutifan
1
atezolizumab
1
aflibercept
1
abemaciclib
1
X-Rays
1
Salts
1
Phantoms, Imaging
1
PM 01183
1
Methods
1
LY2940680
1
Interleukin-13
1
Injections
1
Immunoglobulin G
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
belzutifan
×
1 year
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA